BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 20, 2022
Deals

Oct. 19 Quick Takes: ‘Dark genome’ autoimmunity play Nucleome raises £37.5M series A

Plus venture rounds for Orionis, PIC, Inversago; PTC slips after pausing Huntington trial and more
BioCentury | Apr 7, 2021
Distillery Therapeutics

eIF4E identified as target in obesity, fatty liver disease

DISEASE CATEGORY: Endocrine/metabolic
INDICATION: Obesity; liver disease Reducing levels of eIF4E or lowering the RNA cap-binding protein’s activity by blocking its phosphorylation could
BioCentury | Oct 13, 2020
Product Development

Data Bytes: coronavirus-targeted small molecules

The SARS-CoV-2 protease is the top target for small molecule COVID-19 candidates developed with a coronavirus infection as their original indication, of which only a handful have entered the
BioCentury | Feb 27, 2020
Product Development

Amgen banks on speed to maintain edge in two hot cancer spaces

Amgen’s clinical development strategy aims to make the most of its head start in bispecifics, KRAS
BioCentury | Jan 9, 2020
Product Development

Pfizer dips into translational regulation for cancer with eFFECTOR deal

Pfizer’s deal with eFFECTOR points to translational regulators as an emerging target source
BioCentury | May 24, 2019
Emerging Company Profile

Anima opens new target space in translational control

How Anima is leveraging its translational control platform to pursue new targets, small molecules and big pharma deals
BioCentury | Nov 15, 2017
Distillery Therapeutics

Neurology

BioCentury | Aug 9, 2017
Distillery Therapeutics

Neurology

Items per page:
1 - 10 of 33